Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4081 USD | -6.40% | -3.84% | +32.07% |
May. 15 | Brookline Capital Upgrades Dare Bioscience to Buy From Hold, Price Target is $3 | MT |
May. 14 | Transcript : Daré Bioscience, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Financials (USD)
Sales 2024 * | 2.62M | Sales 2025 * | 27.84M | Capitalization | 43.85M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -10M | EV / Sales 2024 * | 16.7 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.58 x |
P/E ratio 2024 * |
-1.72
x | P/E ratio 2025 * |
-3.6
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.36% |
Latest transcript on Daré Bioscience, Inc.
1 day | -6.40% | ||
1 week | -3.84% | ||
Current month | +32.72% | ||
1 month | +33.41% | ||
3 months | -19.00% | ||
6 months | +16.60% | ||
Current year | +32.07% |
Managers | Title | Age | Since |
---|---|---|---|
Sabrina Johnson
FOU | Founder | 57 | 14-12-31 |
Annie Thurman
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Jessica Hatheway
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robin Steele
BRD | Director/Board Member | 68 | 14-12-31 |
Cheryl Blanchard
BRD | Director/Board Member | 59 | 19-11-19 |
Chairman | 75 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 0.4081 | -6.40% | 347,426 |
24-05-24 | 0.436 | -4.09% | 557,042 |
24-05-23 | 0.4546 | +13.65% | 421,446 |
24-05-22 | 0.4 | -5.75% | 492,908 |
24-05-21 | 0.4244 | -30.43% | 2,078,540 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.07% | 43.85M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- DARE Stock